Price
CHART BY
Frequently asked questions
What is Nuvation Bio's market capitalization?
The market capitalization of Nuvation Bio is $1.12B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Nuvation Bio?
Nuvation Bio's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.628. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Nuvation Bio's stock?
Currently, 8 analysts cover Nuvation Bio's stock, with a consensus target price of $8.143. Analyst ratings provide insights into the stock's expected performance.
What is Nuvation Bio's revenue over the trailing twelve months?
Over the trailing twelve months, Nuvation Bio reported a revenue of $14.36M.
What is the EBITDA for Nuvation Bio?
Nuvation Bio's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$223.59M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Nuvation Bio?
Nuvation Bio has a free cash flow of -$168.58M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Nuvation Bio have, and what sector and industry does it belong to?
Nuvation Bio employs approximately 220 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Nuvation Bio's shares?
The free float of Nuvation Bio is 230.22M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $1.12B
- EPS (TTM)
- -$0.628
- Free Float
- 230.22M
- Revenue (TTM)
- $14.36M
- EBITDA (TTM)
- -$223.59M
- Free Cashflow (TTM)
- -$168.58M
Pricing
- 52W span
- $1.54$4.085
Analyst Ratings
The price target is $8.143 and the stock is covered by 8 analysts.
Buy
8
Hold
0
Sell
0
Information
Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.
- Employees
- 220
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- NUVB
Fundamentals & EOD data from FactSet